Tenth People's Hospital affiliated to Tongji University School of Medicine, Shanghai, 200072 China.
University of Nebraska Medical Center, Omaha, NE 68198-5930 USA.
Transl Neurodegener. 2015 Apr 18;4:7. doi: 10.1186/s40035-015-0028-y. eCollection 2015.
Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.
阿尔茨海默病（AD）是一种突出的痴呆症，其特征是淀粉样β肽（Aβ）斑块和神经原纤维缠结的聚集、突触和神经元的丧失以及认知功能的退化。目前，尽管有多种药物可以缓解一些症状，但 AD 尚无治愈方法。干细胞领域的最新突破为 AD 的治疗提供了有希望的策略。包括胚胎干细胞（ESCs）、神经干细胞（NSCs）、间充质干细胞（MSCs）和诱导多能干细胞（iPSCs）在内的干细胞都有希望用于 AD 的治疗。然而，细胞来源的限制、安全性问题和伦理问题限制了它们在 AD 中的应用。最近，诱导神经祖细胞（iNPCs）的直接重编程为 AD 的治疗带来了曙光。在这篇综述中，我们将讨论直接重编程在 AD 治疗中的最新进展、挑战和潜在应用。
Zotero 插件